Table 2

Characteristics of Patients With MS Stratified by Exercise Capacity and Univariate Analyses to Explore the Contribution of Different Exercise Parameters on Maximal Exercise Capacity (Vo2max)

MS Reduced Exercise Capacity (n = 10)MS Preserved Exercise Capacity (n = 10)p Value for Univariatep Value for Student t Test
Age, yrs68.5 ± 9 (51–79)60.5 ± 9 (37–73)0.070.07
NYHA functional classI: 0 II: 3
III: 7, IV: 0
I: 0 II: 7
III: 3, IV: 0
0.1
Female8 (80)8 (80)0.31.0
Atrial fibrillation2 (20)4 (40)0.70.3
Height, m157 ± 7 (150–169)166 ± 7 (158–178)0.0010.006
Weight, kg68.9 ± 15.0 (50–91)69.5 ± 12.0 (58–98)0.30.9
β-blockers8 (80)7 (70)0.80.6
Ejection fraction, %65.4 ± 9.0 (53–78)67.5 ± 9.0 (55–78)0.60.6
End-diastolic volume index, cc/m268.9 ± 13.0 (51–88)54.9 ± 12.0 (43–81)0.050.02
End-systolic volume index, cc/m223.7 ± 7.5 (13–35)19.1 ± 5.2 (11–27)0.30.1
LAVI, cc/m264.3 ± 27.0 (35.8–120.0)71.8 ± 55.0 (35.2–217.0)0.50.7
Stroke volume, cc/beat63 ± 16 (42–96)68 ± 20 (46–100)0.90.5
Cardiac index, l/min/m22.8 ± 0.8 (1.6–4.0)3.0 ± 1.2 (1.6–5.5)0.90.7
E', cm/s4.5 ± 1.3 (2.0–7.4)4.8 ± 1.4 (3.2–7.0)0.30.7
E/e', ratio34.9 ± 23.0 (19–72)33.6 ± 12.0 (16–54)0.60.9
S', cm/s4.3 ± 1.3 (2.3–7.0)5.3 ± 0.9 (4.1–6.3)0.10.09
Mean mitral gradient5.5 ± 2.7 (2–12)5.0 ± 3.9 (2–15)0.30.8
Mitral valve area continuity1.3 ± 0.5 (0.8–2.1)1.4 ± 0.4 (1.0–2.4)0.40.3
SPAP, mm Hg46 ± 17 (30–84)36 ± 13 (18–62)0.020.07
Wilkins score10.2 ± 2.8 (7–15)7.5 ± 1.9 (5–10)0.0070.004
FVC, l1.6 ± 0.4 (1.05–2.3)2.5 ± 0.7 (1.5–3.9)0.00010.003
FVC, % predicted72 ± 15 (50–96)88 ± 15 (54–103)0.010.03
FEV1, l/s1.3 ± 0.3 (0.95–1.8)2.1 ± 0.6 (1.3–3.4)<0.00010.002
FEV, % predicted71 ± 13 (56–96)88 ± 14 (55–104)0.0030.01
End-diastolic volume index @ peak61.6 ± 14.0 (46.6–90.1)56.1 ± 19.0 (35.2–89.3)0.10.5
End-systolic volume index @ peak21.8 ± 11.0 (12.9–46.3)15.8 ± 7.0 (7.9–29.4)0.040.1
Ejection Fraction (%) @peak65.9 ± 9.0 (49–76)73.5 ± 9.0 (55–85)0.080.1
Tissue Doppler S', cm/sec @peak4.9 ± 2 (2–8)6.1 ± 2.0 (3.9–8.0)0.20.1
Tissue Doppler e', cm/sec @peak5.3 ± 2.2 (3–9)5.9 ± 1.5 (4.0–7.1)0.090.7
Stroke Volume, ml @peak59 ± 16 (40.8–96.0)72 ± 20 (50.5–119.3)0.10.1
Cardiac output, l/min @peak6.1 ± 1.8 (2.4–9.8)9.7 ± 1.8 (7.3–12.9)0.00010.0003
VT @ peak807 ± 160 (633–1,076)1,302 ± 216 (928–1,581)<0.0001<0.0001
A–Vo2 difference @ peak, l/l0.11 ± 0.02 (0.07–0.14)0.11 ± 0.02 (0.08–0.14)0.050.9
Mean mitral gradient @ peak10.6 ± 6.0 (3–22)14.4 ± 6.0 (6.0–22.5)0.20.1
Mitral valve area continuity @ peak1.3 ± 0.4 (0.8–2.0)1.6 ± 0.8 (0.8–3.4)0.70.3
HR @ peak105 ± 24 (60–134)138 ± 25 (105–173)0.00040.007
HR, % predicted65.9 ± 15.0 (38–86)84.4 ± 15.0 (64–109)0.00070.01
O2 pulse max, ml/beat6.6 ± 1.6 (4–8)8.0 ± 1.2 (6–10)0.0040.04
Vo2max, l/min0.7 ± 0.17 (0.37–0.9)1.09 ± 0.2 (0.89–1.4)NA0.0001
Vo2max, % predicted54 ± 16 (34–78)68 ± 11 (52–92)0.00040.04
Vo2/kg max, ml/min/kg10.3 ± 3.5 (6.7–17.5)15.7 ± 3.0 (13.4–21.5)<0.00010.002
Vo2/kg, % predicted64 ± 25 (33–90)82 ± 17 (62–115)0.020.04
SPAP peak77 ± 19 (51–103)72 ± 22 (53–110)0.50.8
Breathing reserve peak27 ± 11 (10–48)48 ± 20 (18.6–92.0)0.030.01
Chronotropic incompetence (corrected for β-blocker)5 (50)1 (10)0.020.04
RER ratio1.05 ± 0.16 (0.97–1.34)1.1 ± 0.09 (0.98–1.27)0.090.3

Values are mean ± SD (range) or n (%) unless otherwise indicated.

A-VO2 difference = arterial–venous difference; O2 pulse = oxygen consumption per cardiac cycle; other abbreviations as in Table 1.